New Markers of Disease Progression in Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by clonal hematopoietic stem cell proliferation.
• Mutations in JAK2, MPL, or CALR genes activate the JAK/STAT pathway, driving PMF pathogenesis.
• PMF presents with diverse clinical features, including anemia, splenomegaly, and increased risk of thrombosis, infection, and leukemic transformation.

Purpose of the Study:

• To review the fundamental aspects of PMF pathogenesis, clinical presentation, and therapeutic strategies.
• To highlight the evolution of prognostic scoring systems in PMF, from classical to molecular markers.
• To discuss emerging biological markers that predict disease progression and patient survival.

Main Methods:

• Literature review of primary myelofibrosis.
• Analysis of pathogenesis, clinical manifestations, and treatment options.
• Evaluation of prognostic scoring systems and biological markers.

Main Results:

• PMF is driven by specific gene mutations leading to JAK/STAT pathway activation.
• Current treatments include symptom management and allogeneic stem cell transplantation as the only curative option.
• Prognosis relies on scoring systems like IPSS, with new molecular markers offering improved patient stratification.

Conclusions:

• Understanding PMF pathogenesis is crucial for developing targeted therapies.
• Advanced prognostic tools, incorporating molecular data, are essential for personalized patient management.
• Continued research into biological markers will refine PMF treatment and improve patient outcomes.